2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1

Bioorg Med Chem Lett. 2005 Aug 15;15(16):3670-4. doi: 10.1016/j.bmcl.2005.05.086.

Abstract

The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A(2A) receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile.

MeSH terms

  • Adenosine A2 Receptor Antagonists*
  • Administration, Oral
  • Animals
  • Catalepsy / drug therapy
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Male
  • Molecular Structure
  • Pyrimidines / chemistry
  • Pyrimidines / classification
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Rats
  • Structure-Activity Relationship
  • Triazoles / chemistry
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use

Substances

  • 2-(2-furanyl)-7-phenyl(1,2,4)triazolo(1,5-c)pyrimidin-5-amine
  • Adenosine A2 Receptor Antagonists
  • Pyrimidines
  • Triazoles